Use of derivatives benzofuroxan in the treatment of angina
The invention relates to medicine, namely to the use of compounds of the number benzofuroxan as a means for treating angina. The invention consists of the application of the connection number of benzofuroxan General formula (I) and its pharmaceutically acceptable salts as tolerant-resistant donor of nitric oxide for the treatment of angina. The invention improves the efficiency of the treatment. 4 C. and 38 C.p. f-crystals, 3 tab., 2 Il.
Description text in facsimile form (see graphic part). T3
Claims
1. Connection usage of a number of benzofuroxan General formula
and its pharmaceutically acceptable salts as tolerant sustainable donor of nitric oxide for treatment of angina pectoris, where R represents halogen, acetoxy, -X-R', -C(O)NR"R"' or -- C(O)CL, where X represents oxygen, sulfur, -C(O)- or-C(O)O-, R' represents hydrogen, linear or branched lower alkyl (C1-C8), R" and R"' independently represent hydrogen, linear or branched lower alkyl (C1-C8or R" and R"' are connected with each other together with the heteroatom or without gateroad is out on p. 1, where substituent R is 5(6) position.3. Application under item 2, where the specified compound is 5(6)-isopropoxycarbonyl-benzofuroxan.4. Application under item 2, where the specified compound is 5(6)-n-propoxycarbonyl-benzofuroxan.5. Application under item 2, where the specified compound is 5(6)-methoxycarbonyl-benzofuroxan.6. Application under item 2, where the specified compound is 5(6)-chlorocarbonyl-benzofuroxan.7. Application under item 2, where the specified compound is 5(6)-tert-butylaminoethyl-benzofuroxan.8. Application under item 2, where the specified compound is 5(6)-etoxycarbonyl-benzofuroxan.9. Application under item 2, where the specified compound is 5(6)-formyl-benzofuroxan.10. Application under item 2, where the specified compound is 5(6)-isopropylaminocarbonyl-benzofuroxan.11. Application under item 2, where the specified compound is 5(6)-n-propylmercaptan-benzofuroxan.12. Application under item 2, where the specified compound is 5(6)-chloro-benzofuroxan.13. Application under item 2, where the specified compound is 5(6)-tert-butoxycarbonyl-benzofuroxan.14. Application under item 2, where the specified compound is 5(6) s is the silt-benzofuroxan.16. Application under item 2, where the specified compound is 5(6)-dimethylaminobenzoyl-benzofuroxan.17. Application under item 2, where the specified compound is 5(6)-[(4-methyl)piperazine-1-yl]carbonyl-benzofuroxan.18. The pharmaceutical composition as tolerant sustainable donor of nitric oxide in the treatment of angina, containing a pharmaceutically active amount of the compounds of General formula I, as defined in paragraph 1 and a pharmaceutically acceptable carrier.19. The pharmaceutical composition under item 18 in the form of the oral composition.20. The pharmaceutical composition according to p. 18, where the specified pharmaceutically acceptable carrier is chosen from one or more compounds selected from the group consisting of starch, lactose, polyvinylpyrrolidone (k-30), talc and magnesium stearate.21. The pharmaceutical composition under item 18 in the form of a parenteral composition.22. A method of obtaining a parenteral composition according to p. 21, which includes the dissolution of the active ingredient of General formula I in polyethylene glycol 400 and dilution thus obtained solution of saline or water to the desired concentration.23. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active connection is whether 21, where the active compound of formula I is 5(6)-n-propoxycarbonyl-benzofuroxan.25. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-methoxycarbonyl-benzofuroxan.26. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-chlorocarbonyl-benzofuroxan.27. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-tert-butylaminoethyl-benzofuroxan.28. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-etoxycarbonyl-benzofuroxan.29. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-formyl-benzofuroxan.30. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-isopropylaminocarbonyl-benzofuroxan.31. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-n-propylmercaptan-benzofuroxan.32. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-chloro-benzofuroxan.33. The pharmaceutical composition according to paragraphs.18 - 20 Icesa song on the PP.18 - 20 or 21, where the active compound of formula I is 5(6)-aminocarbonyl-benzofuroxan.35. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-methylmercapto-benzofuroxan.36. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-morpholinoethyl-benzofuroxan.37. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-dimethylaminobenzoyl-benzofuroxan.38. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-[(4-methyl)piperazine-1-yl] carbonyl-benzofuroxan.39. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is the hydrochloride 5(6)-hydroxy-benzofuroxan.40. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-acetoxy-benzofuroxan.41. The pharmaceutical composition according to paragraphs.18 - 20, or 21, where the active compound of formula I is 5(6)-carboxy-benzofuroxan.42. A method of treating angina in a mammal, including man, comprising introducing an effective amount of compounds of General formula ICL, where X is oxygen, sulfur, -C(O)- or-C(O)O-, R' represents hydrogen, linear or branched lower alkyl (C<sub>1</sub>-C<sub>8</sub>), R)
1-C8or R" and R"' are connected with each other together with the heteroatom or without heteroatoms, such as oxygen or nitrogen, where Vice nitrogen is hydrogen or lower alkyl.
Same patents:
The invention relates to medicine
A method of treating metabolic syndrome // 2207855
The invention relates to medicine and relates to the treatment of metabolic syndrome
The invention relates to pharmaceutical compositions containing the inhibitor nm g COA reductase (E.)-7-[4-(4-forfinal)-6-isopropyl-2-[methyl(methylsulphonyl)amino] pyrimidine-5-yl]-(3R, 5S)-3,5-dihydroxide-6-envoy acid or its pharmaceutically acceptable salt as an active ingredient
The invention relates to the field of medicine and relates to a method of increasing the expression of molecular chaperone cell and/or increasing the activity of molecular chaperones in cells by treating the cells an effective amount of hydroxylamine derivative of the formula (I) or (II), as well as to new derivatives of hydroxylamine and farmkompanijam based on them
The invention relates to medicine, specifically to the preparations for the prevention and treatment of various forms of ischemic heart disease, atherosclerosis, and acute circulatory disorders, cerebral stroke
The use of the r-enantiomer of n-propargyl-1-aminoindan, its salts and compositions containing them // 2203653
The invention relates to medicine, namely, neurology, and for the treatment of cerebral vascular shock
The invention relates to medicine, namely cardiology, and for the treatment of alexithymia (violations recognition and describe their own feelings), in patients with angina
The invention relates to benzodiapines General formula I, their derivatives and analogues
-converting enzyme)" target="_blank">
-converting enzyme)The invention relates to novel ortho-sulfonamidophenylhydrazine heteroaryl hydroxamic acids of the formula
< / BR>where W and X are both carbon, T is nitrogen, U represents CR1where R1represents hydrogen, or alkyl containing 1-8 carbon atoms, R represents-N(CH2R5)-SO2Z, Q represents -(C=O)-NHOH, with
< / BR>is a benzene ring, or is a heteroaryl ring of 5 to 6 atoms in the cycle, which may contain 0-2 heteroatoms selected from nitrogen, oxygen and sulfur, in addition to the heteroatom of nitrogen, denoted as W, where benzene or heteroaryl ring may optionally contain one or two substituent R1where permissible; Z is phenyl, which is optionally substituted by phenyl, alkyl with 1-8 carbon atoms, or a group OR2; R1represents halogen, alkyl with 1-8 carbon atoms, alkenyl with 2-6 carbon atoms, perfluoroalkyl from 1 to 4 carbon atoms, phenyl, optionally substituted by 1-2 groups OR2group-NO2group -(CH2)nZ, where Z is a phenyl which allows an alkyl with 1-8 carbon atoms, phenyl, optionally substituted with halogen, or heteroaryl radical containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R5represents hydrogen, alkyl with 1-8 carbon atoms, phenyl, or heteroaryl containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; or their pharmaceutically acceptable salts
< / BR>where W and X are both carbon, T is nitrogen, U represents CR1where R1represents hydrogen, or alkyl containing 1-8 carbon atoms, R represents-N(CH2R5)-SO2Z, Q represents -(C=O)-NHOH, with< / BR>is a benzene ring, or is a heteroaryl ring of 5 to 6 atoms in the cycle, which may contain 0-2 heteroatoms selected from nitrogen, oxygen and sulfur, in addition to the heteroatom of nitrogen, denoted as W, where benzene or heteroaryl ring may optionally contain one or two substituent R1where permissible; Z is phenyl, which is optionally substituted by phenyl, alkyl with 1-8 carbon atoms, or a group OR2; R1represents halogen, alkyl with 1-8 carbon atoms, alkenyl with 2-6 carbon atoms, perfluoroalkyl from 1 to 4 carbon atoms, phenyl, optionally substituted by 1-2 groups OR2group-NO2group -(CH2)nZ, where Z is a phenyl which allows an alkyl with 1-8 carbon atoms, phenyl, optionally substituted with halogen, or heteroaryl radical containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R5represents hydrogen, alkyl with 1-8 carbon atoms, phenyl, or heteroaryl containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; or their pharmaceutically acceptable salts
The invention relates to derivatives of 1,3,4-oxadiazole formula I, where a is a simple bond or-CH2O -; - simple bond or oxygen; D is -(CH2)n- or-CH2SNONCE2-; n = 1 to 4, an integer; R,- NR1R2or-NR1R2R3X, where X is a counterion and R1, R2and R3each independently is hydrogen or C1-4alkyl, or pharmaceutically acceptable salt or solvate
The invention relates to new inclusion complexes of derivatives of 1,2,5-oxadiazol-2-oxide of General formula I, where1=R2=CN or together with the adjacent carbon atoms form annelirovannymi 3,6-bis(lower alkyl)pyridazin-1,2-dioxideis cycle, polycyclic derivatives of glucopyranose General formula II, where if n= 1, R3fragment 11-oxo-18
, 20-Olean-12-EN-29-OIC acid of the formula III, R4=H, R5--D-glucuronidase, R6=R7=H and R8= C(O)OH, or, if n= 7, R3=N, R4and R7- simple connection, R5and R6= H or (CH2CH(CH3)O)mH, where m=1 to 14, and R8=CH2OH or CH2O(CH2CH(CH3)O)mH, where m=1-14, generating nitric oxide and activating the soluble form of guanylate cyclase (RGC), antispasmodic, vasodilator and hypotensive means quick action and platelet aggregation inhibitors, method for their production and pharmaceutical compositions based on
, 20-Olean-12-EN-29-OIC acid of the formula III, R4=H, R5--D-glucuronidase, R6=R7=H and R8= C(O)OH, or, if n= 7, R3=N, R4and R7- simple connection, R5and R6= H or (CH2CH(CH3)O)mH, where m=1 to 14, and R8=CH2OH or CH2O(CH2CH(CH3)O)mH, where m=1-14, generating nitric oxide and activating the soluble form of guanylate cyclase (RGC), antispasmodic, vasodilator and hypotensive means quick action and platelet aggregation inhibitors, method for their production and pharmaceutical compositions based on
A method for the treatment of patients with resistant to pharmacotherapy forms of epilepsy // 2178298
The invention relates to medicine, namely to psychotherapy and neurology
The invention relates to diphenylvinyl heterocyclic compounds of formula 1 in which Het denotes a fragment selected from the group consisting of (A) - (H)
The invention relates to the derivatives of thiophene of the General formula I, in which R1is the formula A1- X1- R3; R2is perhaps the formula A2- X2- R4; ring b is 4-10-membered nitrogen-containing cycloalkyl ring or 5 - or 6-membered nitrogen-containing unsaturated heterocycle; Ar represents an aryl ring or heteroaryl ring; A1, A2and A3may be the same or different and each represents a bond or lower alkylenes group; X1and X2may be the same or different and each represents a bond or a formula-O-, -S-; R3and R4may be the same or different, and each represents a hydrogen atom, cyclic aminogroup or a lower alkyl group, aryl group or aracelio group, or its pharmaceutically acceptable salt
Derivatives of sulfonamides, the method of production thereof and pharmaceutical composition // 2168503
The invention relates to compounds of formula (I):
< / BR>where
-A= B-C= D - represents-CH=CH-CH=CH-group, in which 1 or 2 CH may be replaced by nitrogen;
Ar denotes phenyl or naphthyl, unsubstituted or one-, two - or three-fold substituted with H, Gal, Q, alkenyl with the number of C-atoms up to 6, Ph, OPh, NO2, NR4R5, NHCOR4, CF3, OCF3CN, OR4, COOR4, (CH2)nCOOR4, (CH2)nNR4R5, -N=C=O or NHCONR4R5phenyl or naphthyl;
R1, R2, R3each independently from each other, are absent or represent H, Gal, Q, CF3, NO2, NR4R5, CN, COOR4or CHCOR4;
R4, R5each independently of one another denote H or Q, or together also denote-CH2-(CH2)N-CH2-;
Q denotes alkyl with 1-6 C-atoms;
Ph denotes phenyl;
X denotes O or S;
Gal denotes F, Cl, Br or I;
"n" represents 1, 2 or 3;
and their salts, except 4-methyl-N-(2,1,3-benzothiadiazole - 5-yl)benzosulfimide, 4-nitro-N-(2,1,3-benzothiadiazole-5-yl)- benzosulfimide and 4-amino-N-(2,1,3-benzothiadiazole-5-yl)- benzolsulfonat
< / BR>where-A= B-C= D - represents-CH=CH-CH=CH-group, in which 1 or 2 CH may be replaced by nitrogen;
Ar denotes phenyl or naphthyl, unsubstituted or one-, two - or three-fold substituted with H, Gal, Q, alkenyl with the number of C-atoms up to 6, Ph, OPh, NO2, NR4R5, NHCOR4, CF3, OCF3CN, OR4, COOR4, (CH2)nCOOR4, (CH2)nNR4R5, -N=C=O or NHCONR4R5phenyl or naphthyl;
R1, R2, R3each independently from each other, are absent or represent H, Gal, Q, CF3, NO2, NR4R5, CN, COOR4or CHCOR4;
R4, R5each independently of one another denote H or Q, or together also denote-CH2-(CH2)N-CH2-;
Q denotes alkyl with 1-6 C-atoms;
Ph denotes phenyl;
X denotes O or S;
Gal denotes F, Cl, Br or I;
"n" represents 1, 2 or 3;
and their salts, except 4-methyl-N-(2,1,3-benzothiadiazole - 5-yl)benzosulfimide, 4-nitro-N-(2,1,3-benzothiadiazole-5-yl)- benzosulfimide and 4-amino-N-(2,1,3-benzothiadiazole-5-yl)- benzolsulfonat
The invention relates to derivatives of 5-phenyl-3-(piperidine-4-yl)-1,3,4-oxadiazol-2(MN)-it General formula I, in which R1is a group (C1-C4)alkyl or the group (C3-C7)cycloalkenyl; X1is a hydrogen atom or halogen or the group (C1-C4)alkoxy or or1and X1together, the group of the formula-och2O-, -O(CH2)2-; -O(CH2)2O - or-O(CH2)3O-; X2is a hydrogen atom or amino group; X3is a hydrogen atom or halogen; R2is a hydrogen atom or a possibly substituted group (C1-C6)alkyl, or a phenyl group(C1-C4)alkyl which may be substituted on the phenyl ring, or a phenyl group(C2-C3)alkenyl, or group of phenoxy(C2-C4)alkyl or cyclo(C3-C7)alkylaryl, or group of 2,3-dihydro-1H-inden-1-yl or 2,3-dihydro-1H-inden-2-yl, or gruppa General formula -(CH2)nFROM a-Z, in which n = 1 to 6, a Z - group piperidine-1-yl or 4-(dimethylamino)piperidine-1-yl
FIELD: organic chemistry, medicine, cardiology, pharmacy.
SUBSTANCE: invention relates to a medicinal preparation used in treatment of chronic cardiac insufficiency. The preparation represents 3-methyl-5-[2-(3-tert.-butylamino-2-oxypropoxy)- phenoxymethyl]-1,2,4-oxadoazole hydrochloride. The preparation provides expanding assortment of medicinal agents used in treatment of chronic cardiac insufficiency.
EFFECT: valuable medicinal properties of drug.
5 tbl
